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Abstract
Background: In the quest for novel molecular mediators of glioma progression, we studied the regulation of FBXW7
(hCDC4/hAGO/SEL10), its association with survival of patients with glioblastoma and its potential role as a tumor
suppressor gene in glioma cells. The F-box protein Fbxw7 is a component of SCFFbxw7, a Skp1-Cul1-F-box E3 ubiquitin
ligase complex that tags specific proteins for proteasome degradation. FBXW7 is mutated in several human cancers and
functions as a haploinsufficient tumor suppressor in mice. Any of the identified targets, Cyclin E, c-Myc, c-Jun, Notch1/4
and Aurora-A may have oncogenic properties when accumulated in tumors with FBXW7 loss.
Results: We tested the expression of FBXW7 in human glioma biopsies by quantitative PCR and compared the transcript
levels of grade IV glioma (glioblastoma, G-IV) with those of grade II tumors (G-II). In more than 80% G-IV, expression of
FBXW7 was significantly reduced. In addition, levels of FBXW7 were correlated with survival indicating a possible
implication in tumor aggressiveness. Locus 4q31.3 which carries FBXW7 was investigated by in situ hybridization on biopsy
touchprints. This excluded allelic loss as the principal cause for low expression of FBXW7 in G-IV tumors. Two targets
of Fbxw7, Aurora-A and Notch4 were preferentially immunodetected in G-IV biopsies. Next, we investigated the effects
of FBXW7 misregulation in glioma cells. U87 cells overexpressing nuclear isoforms of Fbxw7 lose the expression of the
proliferation markers PCNA and Ki-67, and get counterselected in vitro. This observation fits well with the hypothesis
that Fbxw7 functions as a tumor suppressor in astroglial cells. Finally, FBXW7 knockdown in U87 cells leads to defects
in mitosis that may promote aneuploidy in progressing glioma.
Conclusion: Our results show that FBXW7 expression is a prognostic marker for patients with glioblastoma. We
suggest that loss of FBXW7 plays an important role in glioma malignancy by allowing the accumulation of multiple
oncoproteins and that interfering with Fbxw7 or its downstream targets would constitute a new therapeutic advance.
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Background
Glioblastoma (glioma grade IV, G-IV), the most common
tumor arising in the central nervous system, is one of the
deadliest cancers with a mean survival of less than one
year [1]. Reliable molecular predictors of survival out-
come as well as novel targets for efficient therapy are
urgently needed to improve life conditions of patients
with glioma.
In this study, we investigated the expression of FBXW7
(also known as hCDC4, hAGO, SEL10) in glioma. FBXW7
encodes one of the 75 F-box proteins identified so far in
mammals [2]. F-box proteins represent the variable recep-
tor component of Skp1-Cul1-F-box (SCF) complexes, that
mediates binding and ubiquitination of specific proteins,
which are consequently recognized and destroyed by the
proteasome. In contrast to other SCF complexes such as
SCFFbxl1 which target both positive and negative regulators
of the cell cycle [3], all known targets of SCFFbxw7 – namely
Cyclin E [4-6], c-Myc [7], c-Jun [8], Notch 1 and 4 [9-11]
and Aurora-A [12] – are cell growth promoters and poten-
tial oncoproteins. Their turn-over can thus be seen as an
ultimate process in tumor suppression control. Indeed,
FBXW7 itself behaves as a haploinsufficient tumor sup-
pressor gene: the loss of one functional allele is enough to
promote epithelial tumor growth in a mouse model [13].
Given the number of its targets and the fact that FBXW7 is
translated into three different isoforms with distinct sub-
cellular localization, possible mechanisms of tumor sup-
pression are bound to be complex and variable depending
upon the cell type in which downregulation occurs.
FBXW7 is mutated in many cancer cell lines and human
tumors such as endometrial, pancreatic and colorectal
cancers [6,14-17]. Mutations of FBXW7 in brain tumors
have not been investigated yet, however the correspond-
ing locus – 4q31.3 – belongs to the most frequently lost
portion of chromosome 4 in glioblastoma [18,19]. As far
as targets are concerned, much attention has been focused
on the misregulation of Cyclin E [20] and c-Myc [21]
whereas other substrates such as Aurora-A and Notch
receptors have not yet been comprehensively investigated.
In tumors, correlations have been demonstrated between
loss of function of FBXW7 and high levels of Cyclin E
[20], and between Cyclin E overexpression and chromo-
somal instability [17]. However, the overall effect of
FBXW7 loss in cancer cells is not straightforward and
seems to vary according to cancer types [16,22]. Fujii and
coworkers recently reported the accumulation of multiple
targets in several FBXW7 mutant cell lines with a variable
extent of increase in expression and even identified a dif-
ferent pattern of accumulation for two ovarian cancer
lines, one accumulating predominantly both Cyclin E and
c-Myc, the other Aurora-A solely [23].
In this study, we investigated the possible misregulation
of Aurora-A and Notch 4 expression in glioma. Aurora-A
is a mitotic kinase required for G2-M transition, centro-
some maturation and alignment of chromosomes at met-
aphase. Its degradation by the proteasome occurs
promptly after metaphase-anaphase transition and is nec-
essary for mitotic exit [24]. In normal cells, the expression
of Aurora-A is thus rhythmic, discrete and detected in
dividing cells only. By contrast, in cancer cells, Aurora-A is
frequently overexpressed indicating its possible involve-
ment in tumorigenesis [25]. Indeed, Aurora-A overexpres-
sion results in centrosome amplification and cytokinesis
failure – both promoting tetraploidization – and transfor-
mation of cells with already acquired checkpoint defects
[26,27]. How does Aurora-A accumulate in cancer cells?
In bladder cancer, AURKA/STK15, the gene encoding
Aurora-A at locus 20q13.2 is commonly amplified and the
resulting overexpression is correlated with critical clinical
parameters such as invasion, metastasis and poor survival
[28]. But the overexpression of Aurora-A is also frequently
seen in tumors with no gain of AURKA at the DNA level
suggesting that other deregulated mechanisms such as
transcriptional activation or failure of a proteolysis com-
ponent are responsible for Aurora-A accumulation. This
may well apply to glioma: Klein and coworkers detected
amplification of AURKA in 26% of malignant glioma
while as much as 67% of the samples eventually overex-
pressed the gene [29].
Unlike all other targets of Fbxw7, Notch4 has not yet been
investigated in human cancers though the protein is onco-
genic when induced in the MMTV (mouse mammary
tumor virus) mouse model [30]. Thus far, Notch4 has
been described as a vascular endothelium specific signal-
ing receptor. Together with its ligand Delta-like 4 (Dll4),
it is involved in vessel development by mediating arterial/
venous specification and vascular remodeling during
embryogenesis [31]. In tumors, Notch4 signaling is acti-
vated in the endothelium and is here again responsible for
vascular maturation [32]. On the other hand, it has been
recently shown that NOTCH4 transcription can be dere-
pressed in non-endothelial cells: in HeLa cells treated with
endothelial growth factors, cell-type-specific AP-1 (activa-
tor protein 1) complexes are activated that are able to
reprogram NOTCH4 expression [33]. This raises the pos-
sibility that tumor cells, which produce high amounts of
proangiogenic factors – like malignant glioma cells – may
ectopically express NOTCH4.
Here we report that expression of FBXW7 is strongly
reduced in G-IV tumors, mostly independent of locus
depletion, and that the levels of FBXW7 expression corre-
late with patient survival. We find that Aurora-A and
Notch4 accumulate in perivascular zones of patient gliob-
lastoma. Proliferation is significantly impaired in gliomaCell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
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cells overexpressing nuclear FBXW7  in vitro suggesting
that it acts as a tumor suppressor in astroglial cells. Finally
we show that knocking down FBXW7 in cultured glioma
cells destabilizes chromosome segregation at mitosis, a
process controlled by several targets of SCFFbxw7 including
Aurora-A.
Results and Discussion
Expression of FBXW7 in glioma patients and correlation 
with survival
FBXW7 expression was evaluated by quantitative RT-PCR
in 56 G-IV and 5 G-II gliomas. G-IV tumors were classified
according to the normalized expression levels of FBXW7
compared to the mean of expression levels in G-II tumors.
FBXW7 is significantly downregulated (<0.75) in more
than 80% G-IV tumors. As illustrated in Fig. 1A, it is
severely decreased of more than 2-fold (<0.5) in most
samples (73,2%). Correlation was next established
between survival time after initial diagnosis of glioblast-
oma and FBXW7 expression levels. As shown in Fig. 1B,
expression levels were heterogeneous, but when classified
into two groups (<0.5 and ≥0.5), a significant difference
of survival time was highlighted (Mann-Whitney U-test, P
= 0.0099). Interestingly, out of 4 tumors collected from
long survivors with G-IV (> 1000 days), 3 displayed nor-
mal FBXW7 levels. Patients classified in the two groups as
in Fig. 1B were next subjected to Kaplan-Meier survival
analysis illustrating that the outcome for patients with
>0.5 levels of FBXW7 is significantly better than for
patients with reduced expression (Fig. 1C). The same
study performed with two related F-box protein encoding
genes, FBXO6 and FBXL1/SKP2, showed a similar hetero-
geneous spectrum of expression but no evidence for sig-
nificant correlation with survival (not shown). While this
study was being conducted, Bredel et al. described an
informative gene profiling of gliomagenesis, from which
FBXW7 emerges as a downregulated inhibitor of the MYC
interacting pathway [34], reinforcing our findings that it is
a highly significant predictor of aggressiveness. Our
results further demonstrate that FBXW7 can be used as a
specific prognostic marker of survival for patients with
glioblastoma. Together with other recently identified
molecular predictors, FBXW7 may enhance comprehen-
sive classification and molecular characterization of glio-
mas with a likely impact on clinical management
including prediction of therapeutic response.
Allelic loss is not the primary cause for low expression of 
FBXW7 in G-IV tumors
In p53+/- mice, the loss of one allele of FBXW7 get prefer-
entially selected in radiation-induced lymphoma cells and
promotes tumor development so that FBXW7 meets the
criteria of a haploinsufficient tumor suppressor gene [13].
In the same study, the authors show that FBXW7 is a direct
transcriptional target of p53 itself. This raises the possibil-
ity that monoallelic deletion on its own may account for
reduced expression of FBXW7 in patient tumors with
active p53 (around 30% of primary glioblastoma [35]).
FBXW7 maps on 4q31.3. Analyses of this region have
been recently conducted in esophageal adenocarcinoma
and identified deletions in 40% of tumors. The sequence
of the remaining allele was wild-type in most of the cases
[36]. Further studies should confirm the functional impli-
cation of monoallelic deletion (rather than loss of hetero-
zygosity) – i.e. the haploinsufficiency of FBXW7 – in this
type of cancer. We sought for 4q31.3 deletions in our
cohort of G-IV patients. The locus specific probe contain-
ing the complete FBXW7 gene sequence was selected from
the RP11 BAC library (clone 300I24) and proved to
hybridize specifically at 4q31 on metaphase normal chro-
mosomes (Fig. 2A). Twenty-eight tumors were subjected
to touchprint dual color FISH analysis using the FBXW7
locus specific probe and a chromosome 4 subcentromeric
probe for chromosome copy number assessment. The pat-
terns of signal distribution in individual nuclei were col-
lected for 50–100 cells per tumor. Representative images
are shown in Fig. 2B–D. Results of this analysis are illus-
trated in the table of Fig. 2. Samples 1 and 2 were tumors
with no significant downregulation of FBXW7 and did
show no deletion of 4q31.3. FISH analysis identified
FBXW7 hemizygous deletions in 31% (8/26) cases with
downregulation. In these cases however, only a minority
(10–23%) of cells exhibited a 4q31.3 loss while other
nuclei were mainly disomic for chromosome 4 with 2
copies of 4q31.3 (see individual patterns in table of Fig.
2). FISH analysis did not detect any imbalanced case so
that 69% of the tumors (18/26) were classified as non-
deleted.
This analysis suggests that only for a minority of glioblas-
toma, monoallelic deletion of 4q31.3 may participate in
reduction of FBXW7 expression. If downregulation is
required for glioblastoma progression, these events may
be selected preferentially in tumor cells that retain P53
expression. Nonetheless, we conclude that allelic loss is
not a recurring cause for reduced FBXW7 expression in
glioblastoma.
Aurora-A and Notch4 accumulate in G-IV tumors
We next asked if the loss of function of Fbxw7 protein may
participate in glioma malignancy by causing accumula-
tion of specific targets. Protein extracts from the biopsies
were examined by western blotting using anti-CyclinE,
anti-c-Myc, anti-Aurora-A and anti-Notch4 antibodies.
Generally, levels of detected proteins were variable
between samples and no significant correlation with
FBXW7 expression could be made. It was striking how-
ever, that Aurora-A was easily detected in over 81% (35/
43) of the samples with significant decrease in FBXW7
expression, whereas it failed under detection threshold inCell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
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Expression of FBXW7 in glioma and correlation to survival Figure 1
Expression of FBXW7 in glioma and correlation to survival. (A) FBXW7 expression was measured by quantitative RT-
PCR in 56 G-IV compared to a pool of 5 G-II. 73% of high grade tumors show very significant low levels of FBXW7 transcripts 
(<0.5). (B) Relative levels of FBXW7 were heterogeneous, but expression defines two groups of patients with different survival 
times after diagnosis. The median survival in the group with FBXW7 levels >0.5 was 490 days, whereas patients with low 
expression (<0.5) had a median survival of 335 days. The difference between the two groups is significant (P = 0.0099, Mann-
Whitney U-test, two-tailed). (C) Patients classified in the two groups as shown in B were subjected to Kaplan-Meier survival 
analysis. Survival curves for the two patient groups differed significantly (P = 0.011; Log-rank test). Note that two patients in 
the >0.5 group were still alive at the time the analysis were performed, more than 2000 days after initial diagnosis.Cell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
Page 5 of 12
(page number not for citation purposes)
G-II with consistent FBXW7 signals (Fig. 3A). The same
tendency was observed for Notch4 but neither for Cyclin
E, nor c-Myc (not shown). This prompted us to investigate
the presence of Aurora-A and Notch4 on sections of glio-
mas of different histological grades. In G-II, Aurora-A was
detected sparsely in less than 5% of the tumor cells (Fig.
3B) as expected from the low proliferation index (Fig. 3E)
and accumulated only in a few tumor areas (Fig. 3C).
Notch4 was strongly associated with α-SMA (alpha
smooth muscle cell actin) positive vessels (Fig. 3D), as
expected from its previously reported role in vessel matu-
ration [37], but was not detected in any proliferating
tumor cells (Fig. 3E). In contrast, both Aurora-A and
Notch4 were strongly detected in distinct areas of aggres-
sive primary glioblastoma (Fig. 3, lower panel). Aurora-A
massively accumulates in tumor cells surrounding vessels
(Fig. 3G &3J). Anti-Notch4 antibody also stains tumor
cells preferentially around vessels in glioblastoma in addi-
tion to the endothelial lining of α-SMA positive arterioles
(Fig. 3H &3K). No accumulation of any of the two pro-
teins was seen in poorly vascularized tumor areas (not
shown).
All in all, two oncoproteins the mitotic kinase Aurora-A
and the signaling receptor Notch4, which levels depend
on FBXW7, are strongly expressed in specific zones of G-
IV tumors, particularly around blood vessels.
FISH using a FBXW7 specific probe to detect allelic loss Figure 2
FISH using a FBXW7 specific probe to detect allelic loss. (A) Specificity of the RP11-300I24 probe containing FBXW7 on 
metaphase chromosomes from normal lymphocytes. The probe is labeled with SpectrumRed. (B-D) Dual color FISH patterns 
of nuclei from frozen touch prints of human glioblastoma. The 4q31.3 probe is labeled green and the CEN4 probe is labeled 
red. (B) normal signal, (C) monosomic for chromosome 4, (D) monoallelic deletion of 4q31.3. The table summarizes the 
results drawn from the FISH analysis for tumors with FBXW7 downregulation and 4q31.3 deletion (samples 3–10). Samples 1 
and 2 are from tumors with no significant downregulation of FBXW7 expression. Control tissues were from reactive lymphad-
enitis. Using 10% as a cut-off value, 18/26 tumors with significant downregulation of FBXW7 are classified as not deleted (not 
detailed in the table).Cell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
Page 6 of 12
(page number not for citation purposes)
Immunodetection of Aurora-A and Notch4, two targets of FBXW7 Figure 3
Immunodetection of Aurora-A and Notch4, two targets of FBXW7. (A) Detection of Aurora-A in human tumors by 
western blotting. The abundance of Aurora-A has been quantified in 5 randomly chosen G-IV and one representative G-II. The 
same blot has been hybridized with anti-actin antibody for loading control and normalization. Aurora-A is detected in 4 out of 
5 G-IV with downregulation of FBXW7. (B-K) Immunohistochemical detection of Aurora-A and Notch4 in human G-II (mid 
panel, bar = 10 μm) and in a primary invasive glioblastoma (lower panel, bar = 100 μm). Nuclei are labeled with DAPI (blue). In 
G-II, Aurora-A detection (red) is mostly sparse (B) and accumulates in only a few tumor areas (C). Notch4 (red) labels only α-
SMA positive (green) vascular structures (D), but not Ki-67 positive (green) proliferating tumor cells (E). By contrast, in inva-
sive primary G-IV (lower panel) of known histology and α-SMA labeling (F, I) discriminating vascular structures (v, vein ; a, arte-
riole), Aurora-A is massively detected in specific zones of G-IV, mostly around vessels (G-J). Notch4 is also detected in some 
tumor cells in addition to the endothelial lining of arterioles (H-K).Cell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
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Overexpression of FBXW7 inhibits proliferation of U87 
cells in vitro
The three isoforms of Fbxw7, α, β, and γ, have a conserved
structure and molecular function but differ in their subcel-
lular localization which is determined by the first alterna-
tive exon. Welcker and coworkers reported that, in U2OS
cells,  α-Fbxw7 is strongly detected in the nucleus, β-
Fbxw7 in the cytoplasm and γ-Fbxw7 is mostly associated
with nucleoli [21]. Hence, the three isoforms are likely to
mediate degradation of specific targets in a localization-
dependent manner. In order to study the effect of FBXW7
misregulation in glioma, U87 cells were transiently trans-
fected with plasmids encoding each FLAG-tagged Fbxw7
isoform. Transfected cells were detected by immunofluo-
rescence using anti-FLAG antibody. As shown in Fig. 4A–
C, the subcellular localization of α-Fbxw7 and β-Fbxw7
was similar to that previously reported for other cell lines
(ie, nucleoplasmic and cytoplasmic respectively) whereas
isoform  γ localization varied according to its level of
expression: weak expression was restricted to the nucleoli
whereas stronger expression was found in the cytoplasm
and/or in the nucleus. We next asked whether Fbxw7 had
an effect on glioma cell proliferation. Cells that express
the proliferation markers PCNA or Ki-67 were scored
among FLAG-positive cells compared to FLAG-negative
cells. As illustrated in Fig. 4D–J, immunodetection of
PCNA was specifically reduced in cells overexpressing
nuclear Fbxw7. Cells overexpressing nuclear isoforms α
and γ also display strongly reduced expression of Ki-67 (P
< 0.0005 and P < 0.01 respectively) whereas expression of
Ki-67 did not significantly change in cells overexpressing
the cytoplasmic isoform β (Fig. 4K).
The effect of Fbxw7 on proliferation was further con-
firmed by showing that nuclear Fbxw7 counterselects
transiently transfected cells in a time-course culture (Fig.
4L): the growth of cells overexpressing α-Fbxw7 or γ-
Fbxw7 is strongly inhibited between 24 and 72 h after
transfection (P < 0.0001 and P < 0.005 respectively)
whereas FLAG negative internal control cells expand of
more than 2-fold. By contrast, overexpression of isoform
β does not significantly affect the growth of U87 cells.
FLAG positive cells were screened for Aurora-A expression
by double immunofluorescence with anti-FLAG and anti-
Aurora-A antibodies. Amongst cells expressing FBXW7 in
the nucleus (n > 400) no Aurora-A staining was detected
compared to untransfected cells out of which 10% were
Aurora-A positive. This mutually exclusive expression pat-
tern suggests that Fbxw7 targets Aurora-A in glioma cells.
This may interfere with cell cycle checkpoint hence the
dramatic reduction of dividing cells. Given the effect of
Aurora-A knockdown, we can anticipate that cells may
then be arrested in the next cycle by the post-mitotic
checkpoint [25], hence their progressive counterselection
in culture.
In summary, these results indicate that nuclear Fbxw7
exerts an inhibitory effect on proliferation of glioma cells
in vitro and therefore support the hypothesis that loss of
nuclear  FBXW7 expression might contribute to tumor
progression in patients with astroglial tumors.
Fbxw7 knockdown causes mitotic defects in U87 cells
In order to examine the consequences of FBXW7 down-
regulation in glioma, U87 cells – that express low levels of
FBXW7 in culture (not shown) – were transfected with
previously described specific siRNAs directed against a
shared exon of FBXW7 [20]. Cells transfected with either
control siRNA or FBXW7 siRNA were grown for 48 hours
and stained with DAPI and anti-Aurora-A antibody.
Nuclei with individualized chromosomes and Aurora-A
positive staining [24] were classified as mitotic and
accounted for at least 4% of cells in independent control
experiments. We compared mitotic figures in FBXW7
knockdown cells to control cells (>100 mitosis for each
group) and found that 98.5% of the figures were normal
in controls and could be assigned to a specific phase as in
Fig. 5A. By contrast, as much as 16% of mitosis in FBXW7
knockdown cells were seen with 3 or 4 spindle poles (Fig.
5B), and there was significantly less normal metaphases
(Fig. 5C). Unexpectedly, the number of mitotic figures
was significantly decreased in FBXW7 knockdown cells.
This suggests that in glioma cells, loss of Fbxw7 function
primarily triggers mitotic defects that could select for ane-
uploid cells with growth advantage in the evolving tumor.
Possible targets that accumulation may cause checkpoint
disturbances and chromosomal instability are Aurora-A
and Cyclin E although they could not be quantitatively
monitored in these transient transfection assays. Cyclin E
accumulation has been shown to raise similar defects in
colorectal cancer cells [17] and is accumulated in tumors
of different types [20] including glioma with poor prog-
nosis [38].
Conclusion
In this study, we have shown that the expression of
FBXW7 is strongly reduced in glioblastoma. Moreover,
FBXW7 emerges as a relevant survival marker for patients
with glioblastoma that warrants further validation in the
clinic. Our results suggest that FBXW7 downregulation
promotes gliomagenesis via the accumulation of onco-
genic cell cycle regulators that control cell division such as
Aurora-A and/or Cyclin E or Notch. The contribution of
each of the targets remains to be investigated in details in
glioma.
Gene therapy with FBXW7 is already foreseen for cancer
[23]. Glioblastoma patients should benefit of an amelio-
rated survival prognosis based on FBXW7 quantification.
Future studies will tell if there is also a way to improveCell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
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Effect of FBXW7 overexpression in glioma cells Figure 4
Effect of FBXW7 overexpression in glioma cells. Immunodetection of FLAG-Fbxw7 (green) in U87, 48 hours after trans-
fection with plasmids encoding each of the three isoforms α (A), β (B), γ (C). Nuclei are labeled with DAPI (blue) and actin 
cytoskeleton with rhodamin-coupled phalloidin (red), bar = 50 μm. α-Fbxw7 localizes to the nucleus, β-Fbxw7 is cytoplasmic, 
γ-Fbxw7 localization varies. It is restricted to the nucleolus at low levels (insert) and leaks in the nucleus and in the cytoplasm 
at higher doses. Example of PCNA detection (red) in U87 cells overexpressing FLAG-Fbxw7 (green) α (D), β (E), γ (F). In 
lower panels (G-I), only the red signal in the same fields is shown. An example of α-Fbxw7-positive PCNA-negative cell is 
shown with arrowhead. bar = 10 μm. Quantification analysis of PCNA expression 48 h after transfection (J). Scoring was estab-
lished on >150 cells per assay. The results (mean of two independent experiments, ± SEM) are expressed as the ratio of 
PCNA+ cells in FLAG+ versus FLAG- cells from the same transfection well. Quantification analysis of Ki-67 expressing cells in 
FLAG- and FLAG+ cells 48 h after transfection (K). Statistical analysis was performed using the Fisher's exact test (n > 150 cells 
for each group). The experiment was repeated twice with similar results. Cell growth after transfection with each isoform 
expression plasmid (L). For each assay, cells were stained with DAPI and anti-FLAG antibody 24 h and 72 h after transfection. 
FLAG positive and negative cells were scored from 20 independent 40×-magnified fields and their 72 H/24 h ratio compared. 
Cells overexpressing nuclear isoforms α and γ are significantly counterselected. Statistical analysis was performed using the 
Fisher's exact test (n > 1000 cells for each assay). The experiment was repeated twice and analyzed once after 48 h with similar 
results.Cell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
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therapy based on Fbxw7 rescue for those with the most
dismal prognosis.
Methods
Cells and tissue collection
U87 human cells glioma (ATCC/LGCpromochem,
Molsheim, France) were maintained in DMEM with 10%
FBS, antibiotics, and L-glutamine. Glioma biopsies were
classified according to the World Health Organization
[39], the median survival of the G-IV group was 379 days
(n = 54 patients, excluding 2 patients still alive at the time
of analysis). Samples were immediately snap-frozen and
stored until further use for protein and RNA purification,
tissue sectioning, and touch printing of interphase nuclei.
All procedures complied with current French laws.
Fluorescence in situ hybridization (FISH) on interphase 
tumor nuclei
The FBXW7 probe contained in BAC clone RP-11 300I24
was labeled by nick translation with SpectrumGreen
dUTP (Abbott-Vysis, France) and co-hybridized with a
chromosome 4 alpha-satellite probe (D4Z1) coupled to
rhodamin (Qbiogene, Illkirch, France). Efficiency and
specificity were assessed on metaphases and interphases
from cultured human lymphocytes. Dual color FISH anal-
ysis were performed on touchprints of frozen tissues as
previously described [40]. The slides were then fixed by
immersion in methanol and methanol/acetic acid baths.
After drying and dehydratation, the probes were added to
each slide. A coverslip was placed over each hybridization
slide and sealed with rubber cement. Slides and probes
Effect of FBXW7 knockdown in glioma cells Figure 5
Effect of FBXW7 knockdown in glioma cells. Normal mitosis figures in control siRNA transfected cells (A) and examples 
of abnormal mitosis in U87 cells transfected with siRNA against FBXW7 (B). Chromosomes are stained with DAPI (blue) and 
spindle poles with anti-Aurora-A antibody (red), bar = 10 μm. Quantification of abnormal mitosis detected as in B, 48 h after 
transfection with siRNA against FBXW7. More than 3400 cells were analyzed for each condition. Aurora-A positive cells as in 
A and B were classified as mitotic and accounted for around 4% of total cells in controls. FBXW7 siRNA-transfected cells 
showed significantly less mitotic figures (72.2% of controls, P = 0.0094), fewer normal metaphases (27.5% of controls, P = 
0.022), but much more abnormal mitoses (7.3 fold compared to controls, P = 0.0042; unpaired t-test, two-tailed).Cell Division 2007, 2:9 http://www.celldiv.com/content/2/1/9
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were co-denatured using the Hybrite Hybridization Sys-
tem (Abbott-Vysis, Rungis, France) at 73°C during 5 min.
Hybridization was performed 24 h at 37°C in a humidi-
fied box. Finally, slides were washed, dehydrated and
nuclei were counterstained with 4,6-diamidino-2-
phenyindole (DAPI) diluted in Vectashield (Abcys, Paris,
France). The microscopic analysis was done by two inde-
pendent observers using a fluorescent Axioplan II micro-
scope (Zeiss, Le Pecq, France). A minimum of 50 tumour
cell nuclei were evaluated for each slide. Hybridization
signals of control (centromere of chromosome 4, CEN4)
and test (FBXW7) probes were counted for each nucleus.
Nuclei were then classified either as 1) deleted (ratio of
control and test probes 2/1, 4/2, 3/1, 4/1,...), 2) imbal-
anced (disproportion of the ratio of control and test
probes such as 3/2, 4/3, 5/3, etc...), or 3) non-deleted
(equal ratio of control and test probes signals). The cut-off
value was determined as the mean + three standard devi-
ations of the percentage of deleted nuclei on control tis-
sues [41]. Finally, a tumor was classified either as deleted
(% of deleted nuclei ≥ cut-off), or as non-deleted (% of
deleted + imbalanced nuclei < cut-off) or as imbalanced
(% of imbalanced nuclei or sum of imbalanced + deleted
nuclei ≥ cut-off).
Real-time quantitative PCR (qPCR)
RNA was purified from biopsies or cultured cells using
RNeasy columns (Qiagen, Courtaboeuf Cedex, France).
RNA quality was checked by electrophoresis and any sam-
ple displaying degraded RNA was excluded from the
study. RNA was reversed-transcribed with SuperScript II
RNase H-Reverse Transcriptase (Invitrogen, Cergy Ponto-
ise Cedex, France) by using oligo (dT)15 priming. Human-
specific primers for qPCR were designed and evaluated for
amplification efficiency. Primer sequences were: α-tubu-
lin (NM_006082), 5'-GAGTGCATCTCCATCCACGTT-3',
5'-TAGAGCTCCCAGCAGGCATT-3',  FBXW7 (target
sequence common to all isoforms), 5'-CCACTGGGCTTG-
TACCATGTT-3', 5'-CAGATGTAATTCGGCGTCGTT-3'.
Real-time PCR was carried out in a MX3000P thermocy-
cler (Stratagene) by using SYBR Green dye (ABgene,
Courtaboeuf Cedex; France). FBXW7 expression was
steady in all G-II samples tested (mean ΔCt = 6.27, SD =
1). Hence, five controls were individually run in parallel
with every G-IV PCR assay, and the mean ΔCt served as
normalization value. Normalization and quantification
were calculated as described previously [42]. All G-IV sam-
ples were tested in a minimum of two independent exper-
iments.
Cell transfection
U87 cells were seeded in LabTek chambers (100000 cells
per well) and transfected the following day with 100 ng
(α) or 500 ng (β and γ) of plasmid containing FLAG-
FBXW7 cDNA [21], Lipofectamine and Reagent Plus (Inv-
itrogen). For knockdown experiments, human FBXW7
specific [20] and negative control siRNAs were purchased
from Eurogentec (Angers, France) and used at a concentra-
tion of 100 nM as previously described [43]. Knockdown
was verified 48 h after transfection by real-time PCR as
described above.
Western blotting and Immunohistochemistry
Primary antibodies were mouse monoclonal anti-FLAG
(Sigma, clone M2), anti-Aurora-A [44], anti-α-SMA
(DakoCytomation, clone M0851), anti-Ki-67 (DakoCyto-
mation, clone M7240), anti-PCNA (Santa Cruz sc-56),
rabbit polyclonal anti-FLAG (Sigma), anti-Notch4 (Santa
Cruz, clone H-225), goat polyclonal anti-actin (Santa
Cruz, clone I-19),
For western blotting, 20 μg of proteins from each tumor
were separated on a 15% SDS-polyacrylamide gel, then
electrotransferred onto a Hybond-S membrane (Amer-
sham, Les Ulis, France). Membranes were blocked in PBST
containing 5% skim milk for 2 h at 4°C, and incubated
with primary antibodies at 1:200 dilution. After washing,
immunocomplexes were identified with secondary anti-
bodies coupled to peroxidase. The blots were visualized
using chemiluminescence (ECL, Amersham – GE Health-
care Europe, Orsay, France). Immunofluorescence was
carried out on 10 μm cryosections of tumors or on U87
cells grown in Labtek chambers. Tissue samples and cells
were fixed in paraformaldehyde, formaline-ethanol
(PCNA detection) or methanol-acetone (Aurora-A) and
incubated after saturation with the primary antibodies at
the concentration recommended by the supplier. After
washing, slides were incubated with secondary antibodies
(Alexa Fluor 488, and 546; 1:2000, Molecular Probes –
Invitrogen) and mounted with Vectashield containing
DAPI for nuclei staining.
Statistical analysis
All statistical analysis and graphs were performed using
GraphPad Prism software.
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